摘要
目的研究不同病理类型及分级胶质瘤细胞MGMT基因甲基化情况。方法收集胶质瘤患者167例的临床标本,检测并对比各类胶质瘤细胞的MGMT基因甲基化、WHO分级情况,分析MGMT基因甲基化与WHO分级及年龄的相关性。结果 167例胶质瘤标本中,共检出86例MGMT基因甲基化,甲基化率51.50%。同时,弥漫型及间变性星形细胞瘤、继发性GBM、少突胶质瘤、少突星形细胞瘤的甲基化率更高,差异有统计学意义。WHO分级为I级3.59%,Ⅱ级38.92%,Ⅲ级27.54%,Ⅳ级29.94%。MGMT基因甲基化的年龄普遍较非甲基化的年龄更大,在弥漫型星形细胞瘤、继发性GBM及少突星形细胞瘤的甲基化年龄显著高于非甲基化,差异有统计学意义。根据Pearson法分析相关性可知,MGMT基因甲基化与WHO分级呈正相关(γ=0.674,P=0.019),与年龄呈正相关(γ=0.732,P<0.001)。结论 MGMT基因甲基化在胶质瘤中具有较高的发生率,尤其是WHO分级Ⅱ-IV级及年龄较高者中,其对胶质瘤的形成及发展具有重要作用。
To study the different pathological types and levels of glioma MGMT gene methylation in clinical situations. Methods 167 cases of patients with glioma clinical specimens were studied. Detection and compared all kinds of glioma MGMT gene methylation, the WHO classification, patient′s age, MGMT gene methylation and the WHO classification were analyzed and the correlation of age. Results In the 167 cases of gliomas specimens, 86 cases were detected MGMT gene methylation, the total methylation rate was 51.50%. At the same time, diffuse and anaplastic astrocytoma, less secondary GMB, tuglioma, (degeneration) methylation rate of astrocytoma were higher than non-methylation patients. The difference was statistically significant. The WHO classification for I level 3.59%, Ⅱ level 38.92%, Ⅲ level 27.54%, Ⅳ level 29.94%. In all kinds of pathological types of glioma, MGMT gene methylation age was common older, diffuse type (anaplastic) astrocytoma, and secondary GBM (anaplastic) oligoastrocytomas methylation tumor significantly than the un-methylation patients, and there were statistical significantly differences . Correlation analysis showed that MGMT gene methylation and WHO classification was based on person method positively correlated ( γ =0.674, P =0.019), was negatively correlated with age ( γ =0.732, P 〈0.001). Conclusions MGMT gene methylation has a high incidence of glioma, especially WHO grade Ⅱ-Ⅳ and older the age of its formation and development of glioma has an important role.
作者
张建伟
田玉旺
张立英
张岩
许春伟
吴继华
Zhang Jianwei;Tian Yuwang;Zhang Liying;Zhang Yan;Xu Chunwei;Wu Jihua(Department of Oncology,Army General Hospital,Beijing 100700,China;Department of Pathology,Army General Hospital,Beijing 100700,China;Affiliated Bayi Brain Hospital,Army General Hospital,Beijing 100700,China;Department of Pathology,Fujian Cancer Hospital,Fuzhou 350014,Fujian,China;Department of Pathology,the 306 Hospital of PLA,Beijing 100101,China.)
出处
《贵州医药》
CAS
2018年第10期1162-1165,共4页
Guizhou Medical Journal